HMA may also be associated with other drugs whose anti-leukemic activity in CBF-AML have been suggested, such as gemtuzumab-ozogamicin [26, 57], or tyrosine-kinase inhibitors dasatinib [58, 59] or midostaurin [60]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.